Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 14/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16686865 | 0.81 | PIM1 (0.38) | — | |
| SCHEMBL1695267 | 0.78 | KDM4E (0.41) | MAPK14MAPK13APP | |
| SCHEMBL1695558 | 0.74 | MAPK14 (0.40) | MAPK14MAPTMEN1KMT2A | |
| SCHEMBL20343820 | 0.73 | MAPK14 (0.33) | MAPK14MAPK13 | |
| SCHEMBL1695177 | 0.69 | SMN1; SMN2 (0.41) | MEN1KMT2A | |
| SCHEMBL1579040 | 0.69 | MET (0.41) | CYP3A4TSHRMAPK1APP | |
| SCHEMBL5765684 | 0.69 | MAPK14 (0.49) | TSHRMAPK14MAPK13MAPT | |
| SCHEMBL5765239 | 0.68 | MAPK14 (0.53) | MAPK14MAPK13MEN1KMT2A | |
| SCHEMBL5766791 | 0.68 | MAPK14 (0.47) | MAPK14LRRK2 | |
| 4,4'-Thiodianiline SCHEMBL49068 | 0.67 | CYP3A4 (1.00) | CYP3A4TSHRMAPK1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557797-B2 | Triazolopyridine derivatives and their therapeutic use | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-10-15 | — | — | US | disclosed |
| US-20120088763-A1 | TRIAZOLOPYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088763-A1 | TRIAZOLOPYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | CNKSR1, MOK, MAPK1 | CYP3A4 1722/4885TSHR 565/4885MAPK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.